Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14339MR)

This product GTTS-WQ14339MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14339MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5369MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ10894MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ15333MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ9529MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ3400MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ6147MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ11596MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ9865MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW